Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma

Area of Science:

• Endocrinology
• Oncology
• Surgical Pathology

Background:

• Differentiated thyroid carcinoma (DTC) accounts for nearly 90% of thyroid cancers.
• Long-term outcomes for DTC have historically varied, necessitating analysis of treatment efficacy.
• Clinical presentation and treatment results for DTC have shown significant improvements over time.

Purpose of the Study:

• To analyze long-term outcomes in a large cohort of differentiated thyroid carcinoma patients.
• To identify prognostic factors influencing mortality and recurrence rates.
• To evaluate the effectiveness of various treatment modalities, including surgery, radiotherapy, and hormone suppression therapy.

Main Methods:

• Retrospective analysis of 792 differentiated thyroid carcinoma patient records from Lahey Clinic Foundation (1950s-1990s).
• Minimum 15-year follow-up for 631 patients.
• Statistical analysis to identify relationships between clinical factors, treatment, and outcomes.

Main Results:

• Decreased incidence of unresectable or metastatic disease at presentation (7% to 1%).
• Identified risk factors for mortality: older age, male sex, extraglandular extension, vascular invasion, capsular involvement, multifocal disease.
• Lymph node metastases demonstrated a protective effect, inversely proportional to mortality, with no deaths in patients with >10 metastases.
• Subtotal thyroidectomy recommended for high-risk patients; lobectomy for low-risk/small tumors.
• Limited or modified neck dissection recommended only therapeutically.
• Radiotherapy post-surgery showed no benefit in mortality or recurrence.
• Thyroid hormone suppression therapy improved mortality in papillary and mixed carcinomas, but not follicular.

Conclusions:

• Treatment advancements have improved outcomes for differentiated thyroid carcinoma.
• Prognostic factors like age, sex, and tumor characteristics significantly impact survival.
• Lymph node status is a critical prognostic indicator.
• Surgical approach should be tailored to risk stratification.
• Adjuvant radiotherapy is not recommended; thyroid hormone suppression therapy is beneficial for specific subtypes.